Literature DB >> 9231687

Potential benefits of eliminating planning target volume expansions for patient breathing in the treatment of liver tumors.

R K Ten Haken1, J M Balter, L H Marsh, J M Robertson, T S Lawrence.   

Abstract

PURPOSE: To investigate potential benefits derived from reduction or elimination of planning target volume (PTV) margins associated with patient breathing through examination of hepatic tumors treated with conformal therapy. METHODS AND MATERIALS: We reviewed the treatment plans of 50 patients who had previously received conformal partial organ liver irradiation for treatment of hepatic malignancies. PTVs for these plans included expansions (1-2 cm) for patient breathing. Data consisted of the three-dimensional dose distributions computed for the conformal plans generated for these volumes, and also for plans using identical beam arrangements but smaller block margins to treat planning target volumes that did not include the expansions for breathing. We calculated effective volumes (V(eff)) and normal tissue complication probabilities (NTCP) using dose-volume histograms for normal liver and analyzed changes in: V(eff), NTCP at the prescription dose, doses associated with selected NTCP levels, and tumor control probabilities (TCP) at these new dose levels.
RESULTS: Elimination of the patient breathing components of the PTVs for these conformal treatments of liver tumors: (a) decreased the average V(eff) by 5%; (b) decreased the average predicted NTCP at the prescription (isocenter) dose used to treat the patients by 4.5%; (c) increased the average target volume (isocenter) dose associated with low (1-10%) predicted normal liver NTCP by 6-8 Gy, which corresponded to (d) a predicted average 6-7% increase in TCP for aggressive liver tumors. Plans with PTV expansions for breathing that occurred mostly within the liver showed greatest potential benefit.
CONCLUSIONS: Elimination of the margin added to hepatic target volumes for patient ventilation could lead to clinically meaningful increases in dose without increasing the predicted frequency of complications.

Entities:  

Mesh:

Year:  1997        PMID: 9231687     DOI: 10.1016/s0360-3016(97)00009-6

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  8 in total

Review 1.  Adaptive management of liver cancer radiotherapy.

Authors:  Kristy K Brock; Laura A Dawson
Journal:  Semin Radiat Oncol       Date:  2010-04       Impact factor: 5.934

2.  Biological impact of geometric uncertainties: what margin is needed for intra-hepatic tumors?

Authors:  Hsiang-Chi Kuo; Wen-Shan Liu; Andrew Wu; Dennis Mah; Keh-Shih Chuang; Linda Hong; Ravi Yaparpalvi; Chandan Guha; Shalom Kalnicki
Journal:  Radiat Oncol       Date:  2010-06-03       Impact factor: 3.481

3.  Dose escalated liver stereotactic body radiation therapy at the mean respiratory position.

Authors:  Michael Velec; Joanne L Moseley; Laura A Dawson; Kristy K Brock
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-07-08       Impact factor: 7.038

4.  3D dosimetric validation of ultrasound-guided radiotherapy with a dynamically deformable abdominal phantom.

Authors:  Charles K Matrosic; Wesley Culberson; Andrew Shepard; Sydney Jupitz; Bryan Bednarz
Journal:  Phys Med       Date:  2021-04-23       Impact factor: 2.685

5.  Feasibility and potential benefits of defining the internal gross tumor volume of hepatocellular carcinoma using contrast-enhanced 4D CT images obtained by deformable registration.

Authors:  Hua Xu; Guanzhong Gong; Hong Wei; Lusheng Chen; Jinhu Chen; Jie Lu; Tonghai Liu; Jian Zhu; Yong Yin
Journal:  Radiat Oncol       Date:  2014-10-16       Impact factor: 3.481

6.  Gated Volumetric-Modulated Arc Therapy vs. Tumor-Tracking CyberKnife Radiotherapy as Stereotactic Body Radiotherapy for Hepatocellular Carcinoma: A Dosimetric Comparison Study Focused on the Impact of Respiratory Motion Managements.

Authors:  KyoungJun Yoon; Jungwon Kwak; Byungchul Cho; Jin-Hong Park; Sang Min Yoon; Sang-Wook Lee; Jong Hoon Kim
Journal:  PLoS One       Date:  2016-11-22       Impact factor: 3.240

7.  Monte Carlo-based lung cancer treatment planning incorporating PET-defined target volumes.

Authors:  Indrin J Chetty; Shaneli Fernando; Marc L Kessler; Daniel L McShan; Cassandra Brooks; Randall K Ten Haken; Feng-Ming Spring Kong
Journal:  J Appl Clin Med Phys       Date:  2005-11-21       Impact factor: 2.102

8.  To gate or not to gate - dosimetric evaluation comparing Gated vs. ITV-based methodologies in stereotactic ablative body radiotherapy (SABR) treatment of lung cancer.

Authors:  Joshua Kim; Qixue Wu; Bo Zhao; Ning Wen; Munther Ajlouni; Benjamin Movsas; Indrin J Chetty
Journal:  Radiat Oncol       Date:  2016-09-22       Impact factor: 3.481

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.